What is the current stock price of Scilex Holding Company (SCLX)?

As of the latest market data, Scilex Holding Company (SCLX) is trading at $6.80. The stock has seen a loss of -3.00% today.

Does Scilex Holding Company (SCLX) pay a dividend?

Based on current data, Scilex Holding Company does not have a confirmed active dividend policy.

What is the market cap of Scilex Holding Company?

The current market capitalization of Scilex Holding Company (SCLX) is approximately unavailable.

SCLX

Scilex Holding Company·Healthcare

6.80

2.996%(−0.21)

Market Closed

6.93

1.912%(+0.13)

After Hours

Last Updated: — ET

52W L: $3.6052W H: $34.27

SCLX NEWS

globenewswire.com

Mar 13

Scilex Holding Company Files Federal Securities Fraud Lawsuit Seeking Recovery of Approximately Ninety-Six (96) Million Misappropriated Collateral Shares of Datavault AI, Inc. from Marc Wade, The St. James Bank & Trust Company Ltd., Omega & Corinth Group Ltd.

PALO ALTO, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has filed a complaint (the “Complaint”) in the United States District Court for the Central District of California against Marc Wade, The St. James Bank & Trust Company Ltd. (“St. James Bank”), Omega & Corinth Group Ltd., and related parties (collectively, the “Wade Defendants”), alleging a scheme involving the unauthorized transfer and sale of approximately 96 million Datavault AI, Inc. (“Datavault”) common shares (“DVLT”) that were pledged as collateral in a stock loan transaction (the “Pledged DVLT Shares”).

accessnewswire.com

Feb 5

Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 2026

Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024.

globenewswire.com

Jan 30

Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets

PALO ALTO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has made a $20 million strategic investment in Quantum Scan Holdings, Inc. (“Quantum Scan”), a breakthrough medical technology company, targeting trillion-dollar market of preventive diagnosis and prognosis of human diseases and illness.

defenseworld.net

Jan 23

Scilex (NASDAQ:SCLX) Trading Up 8.8% – Time to Buy?

Scilex Holding Company (NASDAQ: SCLX - Get Free Report) was up 8.8% during trading on Thursday. The stock traded as high as $11.95 and last traded at $11.53. Approximately 106,019 shares changed hands during mid-day trading, an increase of 58% from the average daily volume of 66,936 shares. The stock had previously closed at $10.60.

Company Profile

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

115

IPO Date

2021-03-05

Beta

1.42

Websitewww.scilexholding.com↗